Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2019, 28(4):168-173

CLARIFY registry: focus on the subgroup of patients with stable angina pectoris

Murín J1, Kamenský G2
1 I. interná klinika LFUK a UNB, Nemocnica Staré Mesto, Bratislava
2 V. interná klinika LFUK a UNB, Nemocnica Ružinov, Bratislava, Slovenská republika

The CLARIFY registry helps us in focusing on patients with stable angina pectoris who are suffering from angina symptoms. It also helps us to compare characteristics of Slovak patients (55 persons) with the characteristics of European patients (without Slovakia, 4864 persons). Furthermore, it enables comparison of our treatments here. Slovak patients are more severely ill (more severe hypertension, obesity, diabetes, less non-smokers, less exercising patients, more patients suffered myocardial infarction, stroke and atrial fibrillation and more patients have heart failure). These patients are less frequent in achieving the targets of blood pressure (50% in Slovakia vs 49.2% in Europe), HbA1c (<7% it is 8% vs 10.6%), LDL-Ch ≤2.6 mmol/l (57.6% vs 39.6%) and heart rate ≤ 60 bpm (18.2% vs 22.6%). This is why we should increase our efforts in obesity prevention, in more intensive hypertension treatment, in diabetes treatment, hypolipidemic treatments, in smoking prevention, and also in the treatment of increased heart rate of our patients - everything with the aim of improving not only the quality of life of patients, but also improving their prognosis. Tab. 5, Ref. 19, on-line full text (Free, PDF) www.cardiologyletters.sks.sk

Keywords: stable angina pectoris; cardiovascular risk factors; metabolic syndrome; treatment of increased heart rate

Published: April 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J, Kamenský G. CLARIFY registry: focus on the subgroup of patients with stable angina pectoris. Cardiology Letters. 2019;28(4-5):168-173.
Download citation

References

  1. Fihn SD, Gardin J, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/ACAI/STS Guidelines on the diagnosis and management of patients with stable ischemic heart disease: a report of many societies. Circulation 2012;126:e354-e471.
  2. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force of the ESC. Eur Heart J 2013;34:2949-3003. Go to original source...
  3. Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J Suppl. 2009;11(Suppl. D):D13D18. Go to original source...
  4. Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from international prospective CLARIFY registry. Eur Heart J 2012;33:2831-2840. Go to original source...
  5. Murín J, Kamenský G. Register CLARIFY - pohľad na slovenské údaje po piatich rokoch. Cardiology Lett 2017;26:236-246.
  6. Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206. Go to original source...
  7. Bangalore S, Steg G, Deedwania P, et al. Betablocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-1349. Go to original source...
  8. Anderson C, Shilane AS Go, et al. Betablocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. JACC 2014;64:247-252. Go to original source...
  9. Fox K, Ferrari R, Tendera M, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337-2345. Go to original source...
  10. Ferrari R. A personalized treatment approach in the management of angina patients. Intern Webinar, Paris, March 29th 2018.
  11. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 2014;171:2080-2090. Go to original source...
  12. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propanolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279288. Go to original source...
  13. Danchin N, Marzilli M, Parkhomenko B, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011;120:59-72. Go to original source...
  14. Svihrová V, Baráková A, Szaboová, et al. Trends in standardized mortality rates for select groups of cardiovascular diseases in Slovakia between 1980 and 2010. Public health 2016;130:43-50. Go to original source...
  15. Kamenský G, Radimská Ľ, Murín J. Národný program prevencie ochorení srdca a ciev 2013. Kampaň MOST 2012 a Jarné dni srdca 2013. Bratislava: AEPress s.r.o.; 2013:123. ISBN 978-8088880-99-8.
  16. Kamenský G, Murín J. MOST. Mesiac o srdcových témach. Implementácia Európskej charty zdravia srdca na Slovensku. Bratislava. AEPress s.r.o.; 2008:159.
  17. Kamenský G, Murín J. MOST. Mesiac o srdcových témach. Svetový deň srdca na Slovensku. Bratislava. AEPress s.r.o.; 2009:151.
  18. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: A 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol 2017 Sep 7. do: 0.1038/nrcardio.2017.131
  19. Divchev D, Stöckl G; study investigators. Treatment of stable angina with a new fixed-dose combination of ivabradine and metoprolol: effectiveness and tolerability in routine clinical practice. Cardiol Ther. 2017;6:239-249. Go to original source...